This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Two CureVac vaccine patents invalidated in UK branch of global dispute with Pfizer, BioNTech

By Abhishek Kumar ( October 8, 2024, 17:40 GMT | Insight) -- Two of German drugmaker CureVac’s patents associated with technology used in making Covid-19 vaccines were declared invalid by a UK court today on grounds of "insufficiency and obviousness." US pharmaceutical giant Pfizer and German vaccine maker BioNTech had argued that the two patents should be invalidated. The judgment makes the UK the first major jurisdiction to issue a substantive ruling on the validity of some of CureVac’s patents.Two of German drugmaker CureVac’s patents associated with technology used in making Covid-19 vaccines were declared invalid by a UK court today on grounds of "insufficiency and obviousness."...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections